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Abstract
Purpose Obstructive sleep apnoea (OSA) is a prevalent
disorder, characterised by collapse of the upper airways
during sleep. The impact of sleep-disordered breathing on
pulmonary function indices is however currently not well
described. The aim of the study was to evaluate diurnal
change in lung function indices in a cohort of patients with
OSA and relate pulmonary function changes to disease
severity.
Methods 42 patients with OSA and 73 healthy control
subjects participated in the study. Asthma and COPD were
excluded in all volunteers following a clinical and spiro-
metric assessment. Spirometry was then performed in all
subjects in the evening and the morning following a
polysomnography study.
Results There was no difference in evening or morning
FEV1 or FVC between patients and control subjects
(p[ 0.05). Neither FEV1 nor FVC changed in control
subjects overnight (p[ 0.05). In contrast, FEV1 signifi-
cantly increased from evening (2.18/1.54–4.46/L) to
morning measurement (2.26/1.42–4.63/L) in OSA without
any change in FVC. The FEV1 increase in OSA was related
to male gender, obesity and the lack of treatment with
statins or b-blockers (all p\ 0.05). A tendency for a direct
correlation was apparent between overnight FEV1 change
and RDI (p = 0.05, r = 0.30).
Conclusions Diurnal variations in spirometric indices
occur in patients with OSA and FEV1 appears to increase
in subjects with OSA overnight. These changes occur in the
absence of change in FVC and are directly related to the
severity of OSA. These findings dictate a need to consider
time of lung function measurement.
Keywords Forced expiratory volume in 1 s  Lung
function  Obstructive sleep apnoea  Overnight changes
Introduction
Obstructive sleep apnoea (OSA) is a common disorder
which is characterised by intermittent complete or partial
collapse of the upper airways during sleep. This results in
overnight hypoxaemia and frequent arousals which may
lead to excessive daytime sleepiness and the development
or worsening of metabolic, cardiovascular and cognitive
disorders [1].
OSA is a disorder which not only affects the upper
airways but can also impact on the intra-thoracic airways.
Indeed, reduced lung volumes, decreased elasticity and
increased resistance of the lower airways are associated
with more severe disease [2–5]. In addition, chronic airway
diseases, including asthma and chronic obstructive pul-
monary disease (COPD), influence the course of OSA
[6, 7]. Lower airway inflammation and oxidative stress are
accelerated in OSA with a direct relationship between
disease severity and the magnitude of lower airways
inflammation [8]. It appears likely that OSA may also
impact on lung volume mechanics.
To date, however there have been no studies evalu-
ating overnight alterations in lung function indices in
OSA. Theoretically, lung function may vary due to two
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main reasons. On one hand, overnight changes in airway
broncho-reactive mediator concentrations were reported
and may influence operational lung volumes [8–12]. On
the other hand, OSA is associated with increased sym-
pathetic and decreased parasympathetic tone during
sleep, especially during apnoeic periods [13–15], which
may result in alterations in resting bronchial tone
[16–18].
The aim of the study was therefore to evaluate diurnal
change in lung function indices in a cohort of patients with
OSA and compare these with a healthy control cohort.
Apart from providing improved understanding regarding
pathophysiology in OSA, this evaluation has important
clinical implications, namely when to perform lung func-
tion testing in patients with OSA.
Methods
Study Subjects and Design
115 adult volunteers were recruited (47 men, 51 ±
15 years, BMI 27.1 ± 5.8 kg/m2). COPD and asthma were
excluded by spirometry and rigorous assessment of medical
history in all subjects. More specifically, we excluded
patients if any of the evening or morning FEV1/FVC ratio
was below 0.70, or if they reported chronic or intermittent
symptoms of wheezing, shortness of breath, chest tightness
and cough. However, no bronchial provocation or bron-
chial reversibility test has been performed. Subjects who
could not perform reliable and reproducible lung function
tests were excluded. Subjects were recruited from patients
attending Sleep Laboratory of Semmelweis University,
Department of Pulmonology (N = 32), and through inter-
net advertisement (N = 83), and none of them has previ-
ously been diagnosed with sleep-disordered breathing.
Accordingly, no subject had used continuous positive air-
way pressure (CPAP) device prior to recruitment. Thirteen
patients were current or ex-smokers, 42 subjects were
previously diagnosed with hypertension, 15 had known
diabetes, 28 had dyslipidaemia and 26 had allergic rhinitis.
None of the subjects had respiratory tract infection
1 month prior to the study.
Medical history was taken, patients filled in the Epworth
Sleepiness Scale, blood pressure and heart rate were
measured and lung function tests were performed in the
evening (between 7 and 8 pm). Subjects then attended a
full-night polysomnography. Blood pressure and heart rate
were measured and lung function tests were repeated
between 7 and 8 am, within an hour after awakening. The
study was approved by the local ethics committee (Sem-
melweis University TUKEB 30/2014) and volunteers gave
their written informed consent.
Polysomnography
Polysomnography was performed as described previously
[9] using Somnoscreen Plus Tele PSG (Somnomedics
GmbH, Germany) according to the guidelines [19].
Apnoea–hypopnoea index (AHI), respiratory disturbance
index (RDI) and oxygen desaturation index (ODI) were
recorded and used as indices for OSA severity.
Spirometry and Blood Pressure Measurement
Spirometry was performed with the Otthon device (Thor
Medical Systems, Budapest, Hungary) according to the
European Respiratory Society guidelines [20]. At least
three technically acceptable lung function measurements
were performed (the difference between the two highest
values for forced vital capacity (FVC) or forced expiratory
volume in one second (FEV1) was\0.150 L). The highest
values of FEV1 and FVC were recorded. Blood pressure
was taken using a mercury sphygmomanometer with cuff
placed on the left upper arm.
Statistical Analysis
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA,
US) and Statistica 12 (StatSoft, Inc., Tulsa, OK, US) were
used for statistical analyses. Data distribution was assessed
with Kolmogorov–Smirnov test which showed a non-
parametric distribution for FEV1 and FVC, but parametric
distribution for FEV1/FVC. Unpaired t test, Mann–Whit-
ney and v2 tests were used to compare clinical variables
between OSA and control groups. Evening-to-morning
changes in lung function were evaluated with Wilcoxon
test and were expressed as D = morning - evening value.
The relationships between lung function values and clinical
variables were assessed with Spearman’s test. Multiple
logistic regression was applied to analyse the effect of
potential covariates for the relationship between lung
function indices and OSA severity. A p value\0.05 was
considered significant. Data are expressed as mean ±
standard deviation and median/range/for parametric and
non-parametric data, respectively.
Results
Subject Demographics and Comparison of OSA
and Control Subjects
Forty-two subjects were diagnosed with OSA (AHI C 5/h)
and 73 volunteers were considered as controls (AHI\ 5/h).
Compared to control subjects, patients with OSA were
more frequently male, older and had a greater BMI.
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Patients also had an increased rate of comorbidities
including hypertension and dyslipidaemia (p\ 0.05).
Twenty-three patients with OSA and thirteen controls were
obese (BMI C 30 kg/m2). The proportion of restrictive
lung disease (FVC as well as FEV1\ 80 % pred. and
FEV1/FVC[ 0.70) was similar in obese patients with OSA
(61 %) and obese controls (46 %, p = 0.39). A higher
number of patients with OSA were treated with statins, Ca
channel blockers, angiotensin-converting enzyme inhibi-
tors (ACEI) and angiotensin receptor blockers (ARB,
p\ 0.01); however, no difference was found in the fre-
quency of b-blocker users (p = 0.72; Table 1). There was
no difference in FEV1, FVC or FEV1/FVC between the two
groups either when they were measured in the evening or in
the morning (all p[ 0.05; Table 2).
Relationship Between Spirometric Indices
and Disease Severity in Patients with OSA
There was an indirect relationship between FEV1 measured
in the evening (expressed as % predicted) and AHI
(p = 0.02, r = -0.34), ODI (p = 0.02, r = -0.35) as
well as RDI (p = 0.01, r = -0.39). Similarly, evening
FVC (% predicted) was associated with AHI (p = 0.04,
r = -0.31; Fig. 1), ODI (p = 0.04, r = -0.31) and RDI
(p\ 0.01, r = -0.39). FEV1 in the morning (% predicted)
was inversely related to RDI (p = 0.03, r = -0.33), and
morning FVC values (% predicted) were negatively asso-
ciated with AHI (p = 0.03, r = -0.33) and RDI
(p = 0.01, r = -0.38). Neither FEV1/FVC ratio nor
absolute lung volumes were related to OSA parameters. In
Table 1 Comparison of clinical
variables of study participants
OSA Control p
Age (years) 64/36–74 46/20–74 \0.01
Gender (male/female) 23/19 24/49 0.02
BMI (kg/m2) 31.1 ± 6.3 24.8 ± 4.0 \0.01
Hypertension (n) 25/17 17/56 \0.01
Diabetes (n) 8/34 7/66 0.14
Dyslipidaemia (n) 19/23 9/64 \0.01
Allergic rhinitis (n) 6/36 20/53 0.09
Medication usage (yes/no)
Statins 11/31 1/72 \0.01
Ca channel blockers 8/34 2/71 \0.01
ACEI or ARB 14/28 7/66 \0.01
B-blockers 8/34 12/61 0.72
Smoking history (ever/never smoker) 5/37 8/65 0.87
Cigarette pack years 0/0–30 0/0–33 0.16
Epworth sleepiness scale 5/0–14 6/0–14 0.10
AHI (1/h) 17.0/5.2–93.3 0.9/0.0–4.8 \0.01
ODI (1/h) 18.8/0.0–119.4 1.0/0.0–18.3 \0.01
RDI (1/h) 27.0/14.2–103.5 10.5/0.6–24.2 \0.01
Significant differences were observed in age, gender, body mass index (BMI), prevalence of hypertension,
dyslipidaemia, statin, Ca channel blocker as well as angiotensin-converting enzyme inhibitor (ACEI) or
angiotensin receptor blocker (ARB) treatment, apnoea–hypopnoea index (AHI), oxygen desaturation index
(ODI) and respiratory disturbance index (RDI). Data are expressed as mean ± standard deviation for
parametric or median/range/for non-parametric data
Table 2 Lung function values in the evening and morning
OSA Control p
FEV1 (L)
Evening 2.18/1.54–4.46 2.75/1.45–5.81 0.12
Morning 2.26/1.42–4.63 2.77/1.52–5.61 0.19
p 0.02 0.74
FVC (L)
Evening 2.60/1.83–5.32 3.28/1.79–6.51 0.17
Morning 2.71/1.77–5.64 3.17/1.79–5.91 0.23
p 0.19 0.97
FEV1/FVC
Evening 0.84 ± 0.05 0.85 ± 0.07 0.26
Morning 0.84 ± 0.06 0.86 ± 0.07 0.11
p 0.78 0.54
Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC)
values and FEV1/FVC ratios in the evening and morning in patients
with obstructive sleep apnoea (OSA) and control subjects. Data are
expressed as median/range/for FEV1 and FVC and as mean ± stan-
dard deviation for FEV1/FVC
Lung
123
addition, no correlation was observed between lung func-
tion and Epworth Sleepiness Scale (p[ 0.05).
To assess the effect of potential covariates (age, gender,
obesity, comorbidities, medication usage and smoking) on
the relationship between lung function and OSA severity,
the OSA group was divided into mild (AHI 5–14.9 1/h,
n = 17), moderate (AHI 15–29.9 1/h, n = 17) and severe
(AHI[ 30 1/h, n = 8) subgroups. Multiple logistic
regression revealed BMI, hypertension, diabetes, dyslipi-
daemia as well as treatment with statin, ACEI, ARB and
b-blocker as significant covariates (all p\ 0.05). In con-
trast, age, gender, smoking, allergy and therapy with a Ca
channel blocker did not contribute to the relationship (all
p[ 0.05).
Overnight Changes in Spirometric Indices
In OSA, there was a significant increase in FEV1 from the
evening to the morning (p = 0.02), while no difference in
FVC (p = 0.19) or FEV1/FVC (p = 0.78) was noted.
Morning and evening FEV1 (p = 0.74), FVC (p = 0.97) or
FEV1/FVC (p = 0.54; Table 2) were not different in the
control group. Analysing factors associated with lung func-
tion changes inOSA, significant relationships were observed
between DFEV1 and height (p = 0.02, r = 0.35), smoking
status (p\ 0.01, r = -0.44) and cigarette pack years
(p\ 0.01, r = -0.44), and a tendency for a positive corre-
lation with RDI (p = 0.05, r = 0.30; Fig. 2) was also noted.
No correlation was observed between changes in lung
function and Epworth Sleepiness Scale (p[ 0.05). With
respect to the effect of gender, a significant FEV1 changewas
observed only in males (p = 0.03), but not in females
(p = 0.25). In addition, FEV1 increased only in patients with
OSA not using statins (p = 0.02) or b-blockers (p = 0.03),
while there was no change in patients on treatment with
statins (p = 0.97) or b-blockers (p = 0.54). Ca channel
blocker, ACEI or ARB therapy did not affect the results.
When the OSA group was divided into obese (n = 23) and
non-obese subgroups (n = 19), a significant FEV1 increase
was found only in obese patients (p = 0.03), while no dif-
ference was observed in non-obese subjects (p = 0.33). In
contrast, there was no change either in the thirteen obese
(p = 0.90) or non-obese (p = 0.63) controls.
Overnight Changes in Blood Pressure and Heart
Rate
In OSA, there was no overnight change either in systolic
(evening to morning: 140/100–190 to 140/110–190 mmHg,
p = 0.97) or diastolic (80/70–120 to 85/60–120 mmHg,
p = 0.97) blood pressure values. However, heart rate
increased in the morning (74/56–91 to 79/60–94/1/min,
p = 0.01). In contrast, a significant drop in morning sys-
tolic (125/90–170 to 120/100–160 mmHg, p\ 0.01) and
diastolic (80/65–110 to 75/60–100 mmHg, p\ 0.01) blood
pressure was observed in control subjects with no change
in heart rate (from 76/44–96 to 76/51–97/1/min, p = 0.24).
Neither absolute values nor changes in blood pressure or
heart rate were related to lung function indices or their
overnight changes (all p[ 0.05).
Discussion
OSA is a common disorder with an unclear pathophysiol-
ogy. Despite the fact that the first report on the association
between lung volumes and OSA was published already
30 years ago [3], changes in the behaviour of the intra-
thoracic airways have not been investigated in this disor-
der. Our study was the first to demonstrate diurnal change
in select lung function parameters in a cohort of well-
characterised patients with OSA with pathophysiological
and clinical implications. We found a significant 80-mL
overnight increase in FEV1 in patients with OSA which
directly related to the overnight apnoeic burden.
Fig. 1 Relationship between forced vital capacity and apnoea–
hypopnoea index in OSA. There was a significant relationship
between apnoea–hypopnoea index (AHI) and forced vital capacity
(FVC) in OSA measured in the evening (p = 0.04, r = -0.31)
Fig. 2 Relationship between overnight FEV1 change and respiratory
disturbance index in OSA. There was a tendency for a direct
relationship between respiratory disturbance index (RDI) and over-
night changes in forced expiratory volume in 1 s in OSA (p = 0.05,
r = 0.30)
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A reduction in end-tidal lung volumes may lead to a
heightened potential for collapse of the upper airways [5].
Indeed, the relationship between reduced lung volume,
increased respiratory resistance and increased severity of
OSA is already described [2–4]. In keeping with these
studies, we also found a significant, albeit weak association
between spirometric indices and OSA severity. Although
obesity may lead to restrictive ventilatory defect, there is a
growing body of evidence linking OSA to impaired lung
function; necessitating the investigation of sleep-disordered
breathing in patients with restrictive parenchymal lung
diseases.
Interestingly, a significant inverse relationship was also
observed between changes in lung function indices and
smoking status. Smoking even without COPD is associated
with impaired respiratory mechanics [21]. Our study sug-
gests that smoking non-COPD OSA patients are prone to
develop overnight fall in FEV1, a feature known in chronic
respiratory diseases [22].
The reasons for the alterations in lung function observed
in the current study remain to be determined. Changes in
lung function potentially result from nocturnal release of
broncho-reactive mediators. Overnight increase in the
levels of potentially bronchoconstrictive 8-isoprostane [10]
and bronchodilator nitric oxide [11, 12] has previously
been reported in the exhaled breath samples in OSA sub-
jects and these mediator changes may be responsible for
the findings reported in the current study. Another possible
explanation is the augmented adrenal-sympathetic tone
during the night in OSA patients [13, 14, 23]. Although
bronchi are innervated by parasympathetic rather than
sympathetic nerves in mammals [16, 18], circulating
adrenalin is a potent bronchodilator in humans [17]. During
apnoeic periods, parasympathetic tone is decreased [24]
and repeated arousal stimuli are associated with increased
sympathetic activity [25], which may also lead to bron-
chodilation. This imbalance between sympathetic and
parasympathetic tone may last even during wakefulness
[15, 26]. In the current study, this fact was supported by the
lack of physiological blood pressure dip and the increase in
heart rate. Although we did not measure circulating cate-
cholamines, previous studies report an increase in the
concentration of blood adrenaline overnight in OSA [23]
and this may contribute to a propensity to bronchodilation
[27].
Not surprisingly, we found significant differences in
age, gender, BMI, the prevalence of comorbidities and
medications between patients and controls. Age did not
influence our results; however, FEV1 increased only in
male patients. The precise explanation for our findings is
not known, but there are certain gender differences in the
distribution of adipose tissue, upper airway anatomy,
control of ventilation and release of hormones [28]. We
found that BMI was a covariate for the relationship of lung
function and OSA severity. In addition, significant eve-
ning-to-morning increase in FEV1 was present only in
obese patients with OSA. Obesity may lead to the devel-
opment of airway hyper-responsiveness both in animals
and humans [29]. The underlying mechanisms include both
mechanical (increased abdominal and chest wall mass as
well as shallow breathing) and humoral (circulating
inflammatory cytokines and hormones, such as leptin or
adiponectin) factors [29]. However, obesity did not
exclusively explain our findings, as no change in lung
function was observed in obese non-OSA subjects.
Patients with OSA were more frequently treated with
medications potentially affecting airway patency. We
found that statin and b-blocker usage significantly blunted
evening-to-morning FEV1 elevation. It is known that
chronic treatment with statins [30] and b-blockers [31]
inhibits airway hyper-reactivity. Furthermore, the sympa-
thetic blockade by b-blockers may contribute to the lack of
FEV1 changes. Of note, although gender, obesity and drug
treatment modified our findings, this study was not pow-
ered to analyse causality of these factors. Therefore, these
effects need to be investigated in further studies.
The limitations of this study include the relatively low
sample size and the lack of objective measurement of
bronchial hyper-reactivity. The sample size was estimated
to find differences in lung function between the OSA and
control groups. Although we reported that there were sig-
nificant differences when the groups were divided
according to gender, obesity and medication usage, the low
sample size in the subgroups limits our ability to fully
determine the influence of these factors.
Lung function exhibits some degree of diurnal variation
in health and chronic airway diseases [22, 32]. It is known
that patients with chronic airway disease other than asthma
(i.e. COPD or allergic rhinitis) and even healthy subjects
may show some degree of bronchial hyper-responsiveness
[33], and obesity may itself predispose towards hyper-re-
sponsiveness without other symptoms of asthma [29]. As
symptoms are imperative constituents of asthma definition,
we believe that by rigorous assessment of medical history,
bronchial asthma was reliably excluded. However, we did
not perform bronchial reversibility or provocation test.
Therefore, further studies are needed to evaluate airway
hyper-responsiveness in obese OSA. Furthermore, as
variability of lung function is well known even in healthy
subjects, multiple evening-to-morning assessment would
provide stronger evidence for our findings. Finally,
although FEV1 is more commonly used to assess airway
obstruction than the measures of airway/respiratory resis-
tance, independent studies using body plethysmography or
forced oscillation technique would be highly informative in
this context.
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In conclusion, FEV1 increased from evening to morning
in patients with untreated OSA and the magnitude of this
change was directly related to the severity of OSA. These
findings may be explained by increased sympathetic tone
or elevated levels of bronchodilator mediators caused by
untreated sleep-disordered breathing. The significant
increase in FEV1 value in some patients (i.e. those with
more severe OSA) may need to be taken into account when
interpreting results of lung function tests. Further studies
are needed to evaluate the mechanisms underlying these
changes and their implications in patients with OSA.
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